Log in

Principia Biopharma News Headlines (NASDAQ:PRNB)

$59.92
+9.24 (+18.23 %)
(As of 03/31/2020 02:33 AM ET)
Today's Range
$49.08
Now: $59.92
$62.15
50-Day Range
$43.50
MA: $59.56
$70.79
52-Week Range
$25.35
Now: $59.92
$75.65
Volume551,410 shs
Average Volume319,233 shs
Market Capitalization$1.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.76

Headlines

Principia Biopharma (NASDAQ PRNB) News Headlines

Source:
DateHeadline
Principia Biopharma Inc (NASDAQ:PRNB) Given Consensus Recommendation of "Buy" by BrokeragesPrincipia Biopharma Inc (NASDAQ:PRNB) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 27 at 1:22 AM
SVB Leerink Brokers Lower Earnings Estimates for Principia Biopharma Inc (NASDAQ:PRNB)SVB Leerink Brokers Lower Earnings Estimates for Principia Biopharma Inc (NASDAQ:PRNB)
www.americanbankingnews.com - March 16 at 1:38 AM
Principia Biopharma Inc (NASDAQ:PRNB) Short Interest UpdatePrincipia Biopharma Inc (NASDAQ:PRNB) Short Interest Update
www.americanbankingnews.com - March 14 at 12:36 PM
SVB Leerink Comments on Principia Biopharma Incs FY2023 Earnings (NASDAQ:PRNB)SVB Leerink Comments on Principia Biopharma Inc's FY2023 Earnings (NASDAQ:PRNB)
www.americanbankingnews.com - March 13 at 3:03 PM
Principia Biopharma (NASDAQ:PRNB) Price Target Raised to $76.00Principia Biopharma (NASDAQ:PRNB) Price Target Raised to $76.00
www.americanbankingnews.com - March 11 at 11:19 AM
Principia Biopharma (NASDAQ:PRNB) Posts Quarterly  Earnings Results, Misses Expectations By $0.02 EPSPrincipia Biopharma (NASDAQ:PRNB) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - March 11 at 9:05 AM
Principia Biopharma EPS misses by $0.02Principia Biopharma EPS misses by $0.02
seekingalpha.com - March 10 at 5:36 PM
Earnings Preview: Principia Biopharma Inc. (PRNB) Q4 Earnings Expected to DeclineEarnings Preview: Principia Biopharma Inc. (PRNB) Q4 Earnings Expected to Decline
finance.yahoo.com - March 10 at 5:36 PM
Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial ResultsPrincipia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results
finance.yahoo.com - March 10 at 5:36 PM
Principia Biopharma Inc.: Setting The Record Straight On BTK InhibitionPrincipia Biopharma Inc.: Setting The Record Straight On BTK Inhibition
seekingalpha.com - February 19 at 12:51 PM
Principia to Present at 9th Annual SVB Leerink Global Healthcare ConferencePrincipia to Present at 9th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 19 at 12:51 PM
Principia Biopharma: Hype Over Multiple Sclerosis "Data" Is OverblownPrincipia Biopharma: Hype Over Multiple Sclerosis "Data" Is Overblown
seekingalpha.com - February 12 at 2:20 PM
First Week of PRNB March 20th Options TradingFirst Week of PRNB March 20th Options Trading
www.nasdaq.com - February 6 at 2:47 PM
Sahm Adrangis Kerrisdale Capital Issues Negative Report on Principia Biopharma Inc. and Announces Conference Call ScheduleSahm Adrangi's Kerrisdale Capital Issues Negative Report on Principia Biopharma Inc. and Announces Conference Call Schedule
www.prnewswire.com - January 27 at 1:29 PM
Principia Biopharma down 9% on bearish Kerrisdale reportPrincipia Biopharma down 9% on bearish Kerrisdale report
seekingalpha.com - January 27 at 1:29 PM
Interesting PRNB Put And Call Options For August 21stInteresting PRNB Put And Call Options For August 21st
www.nasdaq.com - January 17 at 2:37 PM
Principia Biopharma - The Future WorsensPrincipia Biopharma - The Future Worsens
seekingalpha.com - January 13 at 3:23 PM
Principia Announces Expansion of its BTK Franchise with PRN473 TopicalPrincipia Announces Expansion of its BTK Franchise with PRN473 Topical
finance.yahoo.com - January 9 at 5:10 PM
Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated DiseasesPrincipia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases
finance.yahoo.com - January 7 at 10:16 AM
Principia Bio accelerates timeline in study of lead drug in pemphigusPrincipia Bio accelerates timeline in study of lead drug in pemphigus
seekingalpha.com - December 30 at 11:51 AM
Principia Updates PRN1008 Pemphigus Clinical ProgramPrincipia Updates PRN1008 Pemphigus Clinical Program
finance.yahoo.com - December 30 at 11:51 AM
Principia Biopharma Inc. (PRNB): Hedge Funds In Wait-and-See ModePrincipia Biopharma Inc. (PRNB): Hedge Funds In Wait-and-See Mode
finance.yahoo.com - December 13 at 6:04 PM
Principia Biopharma: High Risk/Low RewardPrincipia Biopharma: High Risk/Low Reward
seekingalpha.com - November 30 at 9:17 AM
Principia to Present at the Stifel Healthcare Conference 2019Principia to Present at the Stifel Healthcare Conference 2019
finance.yahoo.com - November 13 at 9:50 AM
BRIEF-Principia Biopharma Reports Q3 Loss Per Share Of $0.93BRIEF-Principia Biopharma Reports Q3 Loss Per Share Of $0.93
www.msn.com - November 7 at 10:29 PM
Principia Biopharma Inc. (PRNB) Reports Q3 Loss, Lags Revenue EstimatesPrincipia Biopharma Inc. (PRNB) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 5 at 11:14 PM
Principia Biopharma EPS misses by $0.08Principia Biopharma EPS misses by $0.08
seekingalpha.com - November 5 at 6:13 PM
Principia Biopharma Out with IPOPrincipia Biopharma Out with IPO
www.baystreet.ca - October 16 at 10:22 AM
Principia Announces Pricing of Public Offering of Common StockPrincipia Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 16 at 5:22 AM
Principia Announces Proposed Public Offering of Common StockPrincipia Announces Proposed Public Offering of Common Stock
finance.yahoo.com - October 15 at 5:19 PM
Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 TrialPrincipia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
finance.yahoo.com - October 15 at 7:18 AM
Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in PemphigusPrincipia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus
finance.yahoo.com - October 10 at 11:20 AM
Should Principia Biopharma (NASDAQ:PRNB) Be Disappointed With Their 13% Profit?Should Principia Biopharma (NASDAQ:PRNB) Be Disappointed With Their 13% Profit?
finance.yahoo.com - September 13 at 4:16 PM
Principia Biopharma Appoints Shawn Tomasello to Its Board of DirectorsPrincipia Biopharma Appoints Shawn Tomasello to Its Board of Directors
finance.yahoo.com - August 30 at 11:37 AM
Principia Biopharma EPS of $0.28Principia Biopharma EPS of $0.28
seekingalpha.com - August 8 at 8:57 PM
Principia Biopharma Reports Second Quarter Financial ResultsPrincipia Biopharma Reports Second Quarter Financial Results
finance.yahoo.com - August 8 at 8:57 PM
Principia Announces Update to Ongoing Phase 2 Clinical Trial in Patients with ITPPrincipia Announces Update to Ongoing Phase 2 Clinical Trial in Patients with ITP
finance.yahoo.com - July 30 at 12:02 PM
Is Principia Biopharma Inc. (PRNB) A Good Stock To Buy?Is Principia Biopharma Inc. (PRNB) A Good Stock To Buy?
finance.yahoo.com - June 29 at 11:01 AM
Principia Biopharma Appoints Patrick Machado to Board of DirectorsPrincipia Biopharma Appoints Patrick Machado to Board of Directors
finance.yahoo.com - June 12 at 4:47 PM
Principia Bios cancer candidate PRN1371 shows encouraging action in early-stage studyPrincipia Bio's cancer candidate PRN1371 shows encouraging action in early-stage study
seekingalpha.com - May 20 at 12:40 PM
Principia Presents Phase 1 Data of PRN1371 in Patients with Metastatic Bladder CancerPrincipia Presents Phase 1 Data of PRN1371 in Patients with Metastatic Bladder Cancer
finance.yahoo.com - May 20 at 12:40 PM
Principia earns $30M milstone on start of MS studyPrincipia earns $30M milstone on start of MS study
seekingalpha.com - May 15 at 11:08 AM
Principia Biopharma Announces First Patient Dosed in Sanofi’s Phase 2b Trial of SAR442168 in Multiple Sclerosis, Triggering $30 Million MilestonePrincipia Biopharma Announces First Patient Dosed in Sanofi’s Phase 2b Trial of SAR442168 in Multiple Sclerosis, Triggering $30 Million Milestone
finance.yahoo.com - May 15 at 11:08 AM
Principia Biopharma to Present at the 2019 Bank of America Merrill Lynch Health Care ConferencePrincipia Biopharma to Present at the 2019 Bank of America Merrill Lynch Health Care Conference
finance.yahoo.com - May 10 at 12:09 PM
Principia Biopharma Reports First Quarter Financial ResultsPrincipia Biopharma Reports First Quarter Financial Results
finance.yahoo.com - May 8 at 12:16 PM
Here’s What Hedge Funds Think About Principia Biopharma Inc. (PRNB)Here’s What Hedge Funds Think About Principia Biopharma Inc. (PRNB)
finance.yahoo.com - May 7 at 11:58 AM
Principia Biopharma Appoints Shao-Lee Lin, M.D., Ph.D. to Board of DirectorsPrincipia Biopharma Appoints Shao-Lee Lin, M.D., Ph.D. to Board of Directors
finance.yahoo.com - April 19 at 11:59 AM
Principia Biopharma: Targeting PemphigusPrincipia Biopharma: Targeting Pemphigus
seekingalpha.com - April 4 at 3:51 PM
Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial ResultsPrincipia Biopharma Reports Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 20 at 11:45 AM
Principia Biopharma Reacquires Rights to Oral Immunoproteasome ProgramPrincipia Biopharma Reacquires Rights to Oral Immunoproteasome Program
finance.yahoo.com - March 11 at 8:19 AM
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel